The FDA has approved Outlook Therapeutics Inc.'s (OTLK) NS-5010/LYTENAVA for the treatment of neovascular age-related macular degeneration, commonly known as wet AMD.
Outlook's LYTENAVA Crosses The FDA Finish Line On Its Fourth Attempt - Now Comes The Commercial Test
